Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.
Rositsa Koleva-KolarovaLászló SzilberhornTamás ZeleiHeleen VellekoopBalázs NagySimone A HuygensMatthijs M VersteeghMaureen P M H Rutten-van MölkenSarah WordsworthApostolos TsiachristasPublished in: Personalized medicine (2023)
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimbursing PM and potential solutions were elicited and supplemented with literature findings to draft a set of recommendations. Key recommendations to overcome the barriers for adequately financing and reimbursing PM in different healthcare systems in Europe included the provision of legal foundations and establishment of large pan-European databases, use of financial-based agreements and regulation of transparency of prices and reimbursement, and creating a business-friendly environment and attractive market for innovation. The recommendations could be used by health authorities for designing a sequence of policy steps to ensure the timely access to beneficial PM.
Keyphrases
- healthcare
- particulate matter
- air pollution
- polycyclic aromatic hydrocarbons
- heavy metals
- public health
- clinical practice
- water soluble
- primary care
- systematic review
- mental health
- palliative care
- risk assessment
- smoking cessation
- machine learning
- young adults
- human health
- big data
- climate change
- low cost
- deep learning